Search research articles
Contact Us
Filters
Showing results (81-90 of 130) with videos related to
Page
of 13
Sort By:
Clinical Breast Cancer
|
May 31, 2018
Oncologic Safety of Gonadotropin-Releasing Hormone Agonist for Ovarian Function Protection During Breast Cancer Chemotherapy
Hee Jeong Kim, Moo Hyun Lee, Jeong Eon Lee, et al.
The Oncologist
|
May 11, 2025
Patient-reported outcomes from DESTINY-Breast04: trastuzumab deruxtecan versus physician's choice of chemotherapy in patients with HER2-low mBC
Naoto T Ueno, Francesco Cottone, Kyle Dunton, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 3, 2017
MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer
Matthew P Goetz, Masakazu Toi, Mario Campone, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 29, 2020
A Phase Ib Study of Alpelisib or Buparlisib Combined with Tamoxifen Plus Goserelin in Premenopausal Women with HR-Positive HER2-Negative Advanced Breast Cancer
Yen-Shen Lu, Keun Seok Lee, Tsu-Yi Chao, et al.
The New England Journal of Medicine
|
June 6, 2019
Overall Survival with Ribociclib plus Endocrine Therapy in Breast Cancer
Seock-Ah Im, Yen-Shen Lu, Aditya Bardia, et al.
Cancer Research and Treatment
|
April 13, 2023
Efficacy of Limited Dose Modifications for Palbociclib-Related Grade 3 Neutropenia in Hormone Receptor-Positive Metastatic Breast Cancer
Seul-Gi Kim, Min Hwan Kim, Sejung Park, et al.
The Lancet. Oncology
|
August 7, 2021
Chemotherapy with or without avelumab followed by avelumab maintenance versus chemotherapy alone in patients with previously untreated epithelial ovarian cancer (JAVELIN Ovarian 100): an open-label, randomised, phase 3 trial
Bradley J Monk, Nicoletta Colombo, Amit M Oza, et al.
Cancer Research and Treatment
|
June 6, 2019
BioPATH: A Biomarker Study in Asian Patients with HER2+ Advanced Breast Cancer Treated with Lapatinib and Other Anti-HER2 Therapy
Sung-Bae Kim, In-Gu Do, Janice Tsang, et al.
European Journal of Cancer (Oxford, England : 1990)
|
October 27, 2023
Clinical activity of nivolumab in combination with eribulin in HER2-negative metastatic breast cancer: A phase IB/II study (KCSG BR18-16)
Se Hyun Kim, Seock-Ah Im, Koung Jin Suh, et al.
Lancet (London, England)
|
September 23, 2020
Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 trial
Elizabeth A Mittendorf, Hong Zhang, Carlos H Barrios, et al.
Page
of 13
Search research articles
Search
Showing results (81-90 of 130) with videos related to
Sort By:
Page
of 13
Clinical Breast Cancer
|
May 31, 2018
Oncologic Safety of Gonadotropin-Releasing Hormone Agonist for Ovarian Function Protection During Breast Cancer Chemotherapy
Hee Jeong Kim, Moo Hyun Lee, Jeong Eon Lee, et al.
The Oncologist
|
May 11, 2025
Patient-reported outcomes from DESTINY-Breast04: trastuzumab deruxtecan versus physician's choice of chemotherapy in patients with HER2-low mBC
Naoto T Ueno, Francesco Cottone, Kyle Dunton, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 3, 2017
MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer
Matthew P Goetz, Masakazu Toi, Mario Campone, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 29, 2020
A Phase Ib Study of Alpelisib or Buparlisib Combined with Tamoxifen Plus Goserelin in Premenopausal Women with HR-Positive HER2-Negative Advanced Breast Cancer
Yen-Shen Lu, Keun Seok Lee, Tsu-Yi Chao, et al.
The New England Journal of Medicine
|
June 6, 2019
Overall Survival with Ribociclib plus Endocrine Therapy in Breast Cancer
Seock-Ah Im, Yen-Shen Lu, Aditya Bardia, et al.
Cancer Research and Treatment
|
April 13, 2023
Efficacy of Limited Dose Modifications for Palbociclib-Related Grade 3 Neutropenia in Hormone Receptor-Positive Metastatic Breast Cancer
Seul-Gi Kim, Min Hwan Kim, Sejung Park, et al.
The Lancet. Oncology
|
August 7, 2021
Chemotherapy with or without avelumab followed by avelumab maintenance versus chemotherapy alone in patients with previously untreated epithelial ovarian cancer (JAVELIN Ovarian 100): an open-label, randomised, phase 3 trial
Bradley J Monk, Nicoletta Colombo, Amit M Oza, et al.
Cancer Research and Treatment
|
June 6, 2019
BioPATH: A Biomarker Study in Asian Patients with HER2+ Advanced Breast Cancer Treated with Lapatinib and Other Anti-HER2 Therapy
Sung-Bae Kim, In-Gu Do, Janice Tsang, et al.
European Journal of Cancer (Oxford, England : 1990)
|
October 27, 2023
Clinical activity of nivolumab in combination with eribulin in HER2-negative metastatic breast cancer: A phase IB/II study (KCSG BR18-16)
Se Hyun Kim, Seock-Ah Im, Koung Jin Suh, et al.
Lancet (London, England)
|
September 23, 2020
Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 trial
Elizabeth A Mittendorf, Hong Zhang, Carlos H Barrios, et al.
Page
of 13